Global Hemostasis Market

Global Hemostasis Market Size Insights Forecasts to 2035

• The Global Hemostasis Market Size Was valued at USD 2.7 Billion in 2024
• The Global Hemostasis Market Size is Expected to Grow at a CAGR of around 6.32% from 2025 to 2035
• The Worldwide Hemostasis Market Size is Expected to Reach USD 5.3 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Hemostasis Market Size Was Worth Around USD 2.7 Billion In 2024 And Is Predicted To Grow To Around USD 5.3 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.32% From 2025 To 2035. The global hemostasis market provides future growth opportunities through multiple factors which include increasing surgical procedures and rising cases of trauma and cardiovascular diseases and the development of new minimally invasive surgical techniques and the higher need for fast blood-clotting products and the growing medical facilities in developing countries.

 

Market Overview

The Global Hemostasis Market Size refers to the worldwide industry focused on products and technologies used to control bleeding and promote blood clotting during surgeries, trauma care, and medical procedures. Hospitals and ambulatory surgical centers use hemostasis products which include topical agents and sealants and adhesives and advanced hemostatic devices. The market expands because there are more surgical procedures which also leads to greater trauma injuries and more people developing cardiovascular diseases. Governments across developed and emerging countries are investing heavily in healthcare infrastructure, emergency care systems, and surgical facilities, further supporting market expansion. The combination of favorable reimbursement policies and regulatory approvals for innovative hemostatic products enables manufacturers to develop advanced and safer bleeding control solutions for global markets.

 

Report Coverage

This research report categorizes the hemostasis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the hemostasis market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the hemostasis market.

 

Driving Factors

The global market today experiences a major trend which shows hospitals throughout the world. The medical field requires various effective products which can control surgical bleeding for different surgical procedures. The American Hospital Association reported that U.S. hospitals reached 6120 facilities in 2022 and this pattern of fast growth will continue throughout the upcoming period. According to a report from American Heart Association the annual number of Coronary Artery Bypass Graft (CABG) surgeries reaches approximately 240000 procedures in the United States. The demand for hemostatic agents will increase throughout the entire forecast period because of these trends.

 

Restraining Factors

One of the main factors which restricts hemostats market growth operates through existing clinical restrictions. The products face limited adoption because they cannot stop uncontrolled bleeding from occurring. The products prove effective in controlling surgical bleeding but their high costs prevent doctors from using them in practice.

 

Market Segmentation

The hemostasis market share is classified into product type and application.

 

• The topical hemostasis products segment dominated the market in 2024, approximately 50% and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the hemostasis market is divided into topical hemostasis products, infusible hemostasis products, and advanced hemostasis products. Among these, the topical hemostasis products segment dominated the market in 2024, approximately 50% and is projected to grow at a substantial CAGR during the forecast period.  The products implement surgical procedures while controlling blood loss to enhance patient results. The growth of the segment occurs because of increasing surgical procedures and rising trauma incidents and physicians who prefer effective topical treatment solutions.

• The general surgery segment accounted for the largest share in 2024, approximately 52% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the hemostasis market is divided into general surgery, neurosurgery, vascular surgery, cardiovascular surgery, and others. Among these, the general surgery segment accounted for the largest share in 2024, approximately 40% and is anticipated to grow at a significant CAGR during the forecast period. Surgeons perform more than 6000 basic and advanced surgical operationsevery year. Effective bleeding control is essential for abdominal and gastrointestinal and soft tissue operations because it helps to decrease surgical complications and speed up patient recovery. The surgical field experiences strong demand because surgical volumes increase and chronic disease rates rise and advanced hemostatic agents become more widely used.

 

Regional Segment Analysis of the Hemostasis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the hemostasis market over the predicted timeframe.

North America is anticipated to hold the largest share of the hemostasis market over the predicted timeframe. The region benefits from three factors which include advanced healthcare infrastructure and high surgical procedure volumes and effective reimbursement systems. The region benefits from three factors which include its first adoption of innovative hemostatic technologies and the presence of major medical device companies and the rising demand for surgical treatment of trauma and cardiovascular diseases.

 

Asia-Pacific is expected to grow at a rapid CAGR in the hemostasis market during the forecast period. The region experiences rising demand because people become more aware of advanced surgical techniques while surgical conditions become more common and healthcare facilities expand and people gain better access to contemporary medical centers. The market experiences additional expansion because the middle-class population grows and healthcare expenditures rise and the government implements programs to enhance medical services. The countries of China India and Japan lead this growth because their healthcare systems handle large patient volumes and their medical facilities use contemporary surgical procedures. The market will experience additional growth because of more people starting private hospitals and clinics and the rising number of medical tourists.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the hemostasis market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Johnson & Johnson (Ethicon)
• Baxter International
• B. Braun Melsungen AG
• CSL Behring
• Grifols S.A.
• Pfizer Inc
• Ferring Pharmaceuticals
• Medtronic plc
• CryoLife (now part of Artivion)
• Siemens Healthineers
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In October 2025, Japan’s Olympus Corporation launched the THUNDERBEAT™ II, a next-generation hybrid surgical energy device that delivered faster hemostatic cutting and secure vessel sealing in laparoscopic and open surgeries. The device featured three energy modes for versatile use and aimed to improve surgical efficiency and clinical outcomes, with commercial rollout beginning in Europe and Japan.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the hemostasis market based on the below-mentioned segments: 

 

Global Hemostasis Market, By Product Type

• Topical Hemostasis Products
• Infusible Hemostasis Products 
• Advanced Hemostasis Products

 

Global Hemostasis Market, By Application

• General Surgery
• Neurosurgery
• Vascular Surgery
• Cardiovascular Surgery
• Others

 

Global Hemostasis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the Global Hemostasis Market by 2035?

A: The market is expected to grow from USD 2.7 billion in 2024 to USD 5.3 billion by 2035, registering a CAGR of 6.32% due to rising surgical procedures and trauma cases.

 

2. Which product type dominated the hemostasis market in 2024?

A: Topical hemostasis products dominated in 2024 with around 50% share, driven by increasing surgical volumes, trauma incidents, and physician preference for effective, easy-to-apply bleeding control solutions.

 

3. Which application segment held the largest market share in 2024?

A: General surgery accounted for the largest share in 2024, supported by high volumes of abdominal and soft tissue procedures requiring efficient bleeding control to reduce complications and recovery time.

 

4. Why does North America lead the hemostasis market?

A: North America leads due to advanced healthcare infrastructure, strong reimbursement policies, early adoption of innovative technologies, and high numbers of trauma and cardiovascular surgeries.

 

5. Why is Asia-Pacific expected to grow the fastest?

A: Asia-Pacific is projected to grow rapidly due to expanding healthcare infrastructure, increasing surgical awareness, rising medical tourism, growing middle-class population, and government initiatives improving healthcare access.